RosVivo Therapeutics is focused on developing innovative therapies for metabolic diseases, particularly targeting diabetes and obesity through the use of microRNA (miRNA) drugs. Their mission emphasizes a commitment to creating breakthrough treatments that leverage the unique properties of miRNA to address these conditions. The company is advancing a pipeline of products, with RSVI-301 and RSVI-302 as the primary candidates, which have shown promising results in both in-vitro and in-vivo models. This research has been recognized in the prestigious journal 'Gastroenterology,' highlighting the scientific credibility of their approach.

The pipeline under development includes a range of therapies aimed at not only diabetes but also obesity and related conditions such as non-alcoholic fatty liver disease (NAFLD) and gastrointestinal disorders. The clinical trial phase for RSVI-301 is expected to pave the way for further applications in treating obesity and other metabolic disorders, demonstrating RosVivo's strategic focus on expanding the therapeutic potential of their miRNA-based drugs. This comprehensive approach positions the company at the forefront of metabolic disease treatment innovation.

United States

RosVivo Therapeutics is a biotechnology company that develops microRNA-based therapeutics for type 2 diabetes, obesity, and fatty liver disease. They have signed a Material Transfer Agreement for first-in-class diabetes treatment with Eli Lilly and Company.

RosVivo Therapeutics

Company Details